Power Law company profile

Ambrx

Biotech & Life Sciences · San Diego, United States · Founded 2003 · IPO 2021 Unicorn

A biopharmaceutical company with a mission to deliver breakthrough protein therapeutics

Valuation

$1.55B

Market cap · 2026

Revenue

$7.4M

Latest reported FY

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026

Investors

22 investors on Ambrx's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 1 investor entered at this stage

M Ventures

Series B+ 21 investors entered at this stage

5AM Ventures

China Everbright Limited

Sinopharm Group

Fidelity Investments

Aravis Ventures

Suvretta Capital Management

Northeast Securities

Cormorant Asset Management

Versant Ventures

Roche Venture Fund

Maverick Capital

Apricot Capital

CMEA Capital

BlackRock

University of California

Berkeley

Adage Capital

Tavistock Group

Maverick Ventures Israel

Invus

Apposite Capital

Ambrx mafia

Startups founded by Ambrx alumni

Former Ambrx employees who went on to start their own companies. Sorted by Dealroom signal score.

Kura OncologyEst. 2014

Troy WilsonUnited States

Signal score90

ArdelyxEst. 2007

PSPeter SchultzUnited States

Signal score84

TRIO PharmaceuticalsEst. 2018

SBShiva BhowmikUnited States

Signal score78

Ablaze PharmaceuticalsEst. 2021

Alan XuChina

Signal score61

Effector TherapeuticsEst. 2012

Kevin EastwoodUnited States

Signal score60

Book a demo to explore the full alumni network →

Global footprint

Where Ambrx has talent and traffic

Workforce by country

2 countries with
team presence

🇺🇸 United States94%

🇨🇳 China3%

2 countries shown

Web traffic by country

1.7K monthly visits
across markets

🇺🇸 United States41.2%

🇹🇷 Turkey29.4%

🇮🇳 India29.4%

Top 3 markets shown

Patent intelligence

$129M patent portfolio · 45 active families

Estimated portfolio value

$129M

8.3% of market cap · 6.7× the top peer Vaxcyte ($19M)

45 active patent families

Where Ambrx innovates Amino acidMolecular biologyAntiendomysial antibodiesCell biologyBiochemistry

Where Ambrx concentrates vs peers

Each axis is a top-10 topic across Ambrx and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Ambrx

An AI-synthesized read of the highest-engagement posts about Ambrx on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Ambrx on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles